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The Pendred syndrome gene (PDS) encodes a transmembrane protein, pendrin, which is expressed in follicular thyroid cells and
participates in the apical iodide transport. Pendrin expression has been studied in various thyroid neoplasms by means of
immunohistochemistry (IHC), Western blot and RT–quantitative real-time PCR. The expression was related to the functional activity
of the thyroid tissue. Follicular cells of normal, nodular goitre and Graves’ disease tissues express pendrin at the apical pole of the
thyrocytes. In follicular adenomas, pendrin was detected in cell membranes and cytoplasm simultaneously in 10 out of 15 cases.
Pendrin protein was detected in 73.3 and 76.7% of the follicular (FTC) and papillary (PTC) thyroid carcinomas, respectively, where
pendrin was solely localised inside the cytoplasm. An extensive intracellular immunostaining of pendrin was observed in six out of 11
(54.5%) of positive FTCs and 19 out of 23 (82%) of PTCs. Focal reactivity was detected in one follicular- and three papillary
carcinomas, whereas pendrin protein was absent in three of 15 FTC and four of 30 PTC; mRNA of pendrin was detected in 92.4% of
thyroid tumours. The relative mRNA expression of pendrin was lower in cancers than in normal thyroid tissues (Po0.001). The
pendrin protein level was found to parallel its mRNA expression, which was not, however, related to the tumour size and tumour
stage. In conclusion, pendrin is expressed in the majority of differentiated thyroid tumours with high individual variability but its
targeting to the apical cell membrane is affected.
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The iodide metabolism and thyroid hormone synthesis in the
thyroid gland is controlled by specialised proteins. The iodine
pathway comprises several steps that involve (1) the transportation
of iodide from the blood stream to the intracellular compartment
by NIS localised in the basal membranes of the follicular cells (Dai
et al, 1996; Smanik et al, 1996) and (2) the intracellular iodide
transportation to the follicular lumen, where iodide accumulation,
oxidation, and organification – key steps of hormonogenesis –
normally occur (Taurog, 2000). The basolateral iodide transport as
well as the NIS, a protein that catalyses this process are well
characterised (Dai et al, 1996; Smanik et al, 1996; Dohan et al,
2003). However, the apical translocation of iodide across
membranes and the protein/s involved are still a matter of debate
in the pathophysiology of the thyroid gland (Everett et al, 1997;
Rodriguez et al, 2002). One of the iodide transporters located at the
apical pole of the thyrocytes is pendrin encoded by the PDS gene
(Pendred syndrome gene), a member of the SCL26A gene family
(Everett et al, 1997; Royaux et al, 2000). Pendrin is a highly
hydrophobic transmembrane protein composed of 780 amino
acids with 12 trans-membrane domains (Everett et al, 1997;
Royaux et al, 2000). In the thyroid, pendrin is localised in the
apical membrane of follicular cells facing the colloid lumen. It was
demonstrated to function as an iodide transporter (Taylor et al,
2002; Yoshida et al, 2002). Electrophysiological studies suggest the
existence of two apical iodide channels (Golstein et al, 1992), and
as recently shown, pendrin mediating vectorial iodide transport
corresponds to one of these channels (Gillam et al, 2004). The
pendrin gene is not under the control of TSH but it is upregulated
by thyroglobulin (Royaux et al, 2000). It has been postulated that
the loss of the transport capability of pendrin may be responsible
for the partial defect of organification, observed in patients with
the Pendred syndrome (Reardon et al, 1999; Scott et al, 1999).
The role of pendrin in the pathophysiology of the thyroid is not
fully understood. Recently, the pendrin gene- and protein
expression have been studied in different thyroid diseases (Bidart
et al, 2000; Arturi et al, 2001; Lacroix et al, 2001; Porra et al, 2002;
Kondo et al, 2003). It was found that the PDS gene transcript level
in thyroid tumours was slightly (Porra et al, 2002) or dramatically
(Bidart et al, 2000; Lacroix et al, 2001) reduced or even absent
(Arturi et al, 2001; Mian et al, 2001), compared to normal thyroid
tissues. Moreover, in thyroid tumours, an aberrant hypermetyla-
tion of the PDS gene was observed (Xing et al, 2003). In hypo- and
hyperfunctioning adenomas, the PDS gene expression and protein
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slevels were within the normal range, while they were increased in
toxic adenomas (Bidart et al, 2000; Arturi et al, 2001). Thyroid
cancers have different defects of the iodide metabolism, which may
occur at each step of the iodide pathway, thus including defects of
the iodide transporters (Hoang-Vu et al, 1992).
Our study has focused on the immunological and immunohis-
tochemical analysis of a series of normal, benign and malignant
thyroid tissues with pendrin-specific antibodies, as well as on the
quantification of the pendrin gene expression. The results indicate
that pendrin is easily detected in most differentiated thyroid
carcinomas on both mRNA and protein levels. Malignant
transformation, however, interferes with proper pendrin traffick-
ing to the apical plasma membrane in tumour cells.
MATERIAL AND METHODS
Thyroid tissues
A total of 155 thyroid tissue samples were provided by the Centre
of Oncology, Department of Surgery as well as by the Pathology
Department of CMKP. After histopathological examination, tissues
were classified according to the WHO recommendations and
selected. Each tumour was scored based on the TNM (tumour-
node-metastasis) classification (Table 2, Sobin and Fleming, 1997).
The samples chosen for the study represented a wide range of
thyroid pathologies such as Graves’ thyroid tissue (GD), n¼10;
nodular goitre (NG), n¼28; follicular adenoma (FA), n¼15;
follicular carcinoma (FTC), n¼15; papillary carcinoma (PTC),
n¼30; medullary carcinoma (MTC), n¼8 and anaplastic carci-
noma (ATC), n¼2, which were compared to the normal thyroid
(NT), n¼47. Tissues obtained after surgery were immediately
frozen and stored in liquid nitrogen until analysis. For Western
blot and RNA isolation, the cancerous tissue was separated from
the surrounding normal thyroid fragments by expert evaluation of
the pathologist.
The local human study ethical committees approved this study
and all patients gave their informed consent.
Antibodies
Two peptides, numbered 1, M-A-A-P-G-G-R-S-E-P-P-Q-L-P-E,
corresponding to the first 15 amino acids (1–15) and peptide 5,
L-D-V-Q-D-E-A-M-R-T-L-A-S, corresponding to the last 13 amino
acids (768–780) of the human pendrin sequence (Everett et al,
1997), were synthesised by the conventional solid phase method,
and used to prepare antipeptide antisera in rabbits. Briefly, the
peptide was conjugated to mariculture keyhole limpet haemo-
cyanin (1mg peptide/1mg haemocyanin) through a terminal
cysteine residue (added at the C-terminal end in peptide 1 or to
the N-terminal end in peptide 5) with sulpho-SMCC (sulphosucci-
nimidyl 4-N-maleimidomethyl cyclohexane-1-carboxylate (Pierce
Chemical Co, Rockford, IL, USA) as a crosslinker according to the
manufacturer’s instruction. This peptide conjugate was then used
for the immunisation procedure (two New Zealand White female
rabbits were injected) according to the standard schedule. Sera
were tested for their antibody titre against the peptide by ELISA.
Appropriate controls with preimmune sera at the same dilutions
were used and controls for nonspecific binding were run parallely.
Then site-specific antipeptide antibodies were purified by
affinity chromatography on peptide-coupled columns (sulpho-link
gel, Pierce Chemical Co.). Both antibodies, to N-, and C-peptides,
produced identical results in immunological studies (Table 1).
RT–real-time PCR analysis
Quantitative RT–real-time PCR analysis for pendrin and b-actin
were performed using the GeneAmp 5700 Sequence Detection
System (PE Applied Biosystems, Foster City, CA, USA). Total RNA
was isolated from frozen thyroid tissues using RNeasy Mini Kit
(QIAGEN, Hilden, Germany). The RNA concentration and purity
were determined by absorbance measurements at 260nm and by
determining the A 260/A 280 ratio. In all, 1mg of total RNA was
reverse-transcribed using SuperScript II RT (GIBCO-BRL,
Gaithersburg, MD, USA) and random hexamers in 20ml of volume
as per the manufacturer’s protocol. The cDNAs were then diluted
1:25 in 10mM Tris-HCl pH 8.0. Oligonucleotide primers and
TaqMan probe for PDS gene (TaqMan Assays-on-demand gene
expression, Id: Hs00166504_m1) and b-actin reference gene (Id:
Hs99999903_m1) products were purchased from PE Applied
Biosystems. DNA polymerase in TaqMAN universal PCR Master
MIX was activated by incubation for 10min at 951C. PCR
amplification was carried out at 40 cycles, consisting of 15s of
denaturation at 951C and hybridisation of primers and a probe
for 1min at 601C in a 96-well reaction plate; all analyses were
performed in duplicate and the mean was calculated. The normal
control thyroid tissue (pool of tissues) was used for the
construction of a standard curve for both PDS and b-actin. Four
differently diluted cDNAs (200ng, 50ng, 12.5ng, 3.125ng in
25mlwell
 1) of the control thyroid were used to construct a
standard curve. The target quantity of pendrin was determined
from the standard curve and divided by the target quantity of
b-actin RNA for normalisation. The relative values of pendrin were
expressed as n-fold differences from the mean values of the normal
thyroid. Quantitative real-time PCR data analysis was carried out
using Microsoft
s Excel
s based software application Q-Gene
(Bernard and Wittwer, 2002; Muller et al, 2002).
PCR amplification efficiencies of the PDS gene and b-actin gene
were as follow: Epds¼1.95 and Eb-actin¼1.96.
Table 1 Immunohistochemical results of pendrin staining
Staining grade
Intense Moderate
Tissues No. of cases m
a m+c c m m+c c Focal No staining
Normal thyroid 47 47
Graves’ disease 10 10
Nodular goiter 28 28
Follicular adenoma 15 1 5 3 5 1
Follicular carcinoma 15 1 6 4 1 3
Papillary carcinoma 30 19 4 3 4
Anaplastic carcinoma 2 2
Medullary carcinoma 8 8
am¼membranous staining; m+c¼membranous and cytoplasmic staining; c¼cytoplasmic staining.
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sSDS–PAGE and Western blotting
Tissue samples were homogenised in an ice-cold buffer (250mM
sucrose, 20mM Tris-HCl, pH 7.4, 1mM EDTA) containing a cocktail
of protease inhibitors (Roche diagnostics GmbH, Mannheim,
Germany). Homogenates were centrifuged at 1000g for 15min at
41C, then at 100000g for 60min at 41C. The resulting pellets
containing particulate fractions were recovered, resuspended in
20mM Tris-HCl, pH 7.4 with 1mgml
 1 PMSF (phenyl-methyl-
sulphonyl fluoride) and kept at  801C. The protein concentrations
were evaluated by the BCA (bicinchoninic acid) protein assay
reagent (Pierce Chemical Co.).
In total, 30mg of crude membrane proteins were mixed with a
protein buffer (0.25mM Tris-HCl, pH 6.8; 20% glycerol; 4% SDS
and 0.1% bromophenol blue) and incubated with 0.125 M
dithiothreitol for 30min at 371C. Each sample was loaded into
individual wells and electrophoresed through a 9% acrylamide,
using SDS–PAGE method. Proteins were electrotransferred to
Immuno-blot PVDF membranes (Bio-Rad Laboratories, Hercules,
CA, USA), which were then saturated with 5% powdered milk in
PBS-Tween (PBS-T). Western blotting experiments were subse-
quently carried out by incubating the blotted membranes for 2h
with anti-pendrin antibody at 1mgml
 1 concentration at room
temperature. After three washings in PBS-T for 10min, the
membranes were incubated with affinity-purified anti-rabbit
antibody labelled with horseradish peroxidase (Jackson Immu-
noResearch Laboratories, West Grove, PA, USA) for 1h at room
temperature under shaking. After extensive washing, membranes
were developed with a chemiluminescent peroxidase substrate
SuperSignal
s West Pico (Pierce Chemical Co.) for 5min at room
temperature, then exposed for 15min to Biomax film MS (Eastman
Kodak Co. Rochester, NY, USA) according to the manufacturer’s
instructions. The free peptide precipitation of primary antibody as
well as secondary antibody controls were included in the series of
Western blots.
Western blot signals were scanned and quantified using KODAK
1D Image Analysis Software (Eastman Kodak Co. Rochester, NY,
USA).
Immunohistochemistry (IHC)
Tissue sections (3mm) mounted on silane-coated glass slides were
deparaffinised in xylene, rehydrated via graded ethanols to water
ratios. After antigen heat retrieval (water bath, 961Ci n1 0m M citric
buffer, pH 6.0, for 20min) and endogenous peroxidase quenching
(3% H2O2 solution for 5min), slides were incubated with site-
directed anti-pendrin antibodies at a concentration of 0.25mgml
 1
overnight at 41C. Then, they were washed and incubated with an
LSAB 2 kit (DakoCytomation, DAKO Corp., Carpinteria, CA, USA),
developed with DAB chromogene, counterstained with Mayer’s
haematoxylin in agreement with the manufacturer’s protocols. The
specificity of the immunostaining was checked by omission of
single steps in the protocol (negative control), by replacement of
the primary antibody with preimmune serum and peptide
competition tests. Immunoreactivity was competitively inhibited
by addition of 10mg of the corresponding synthetic peptides used
to generate Abs.
The positive immunostaining was evaluated using a semi-
quantitative score: 0, negative; þþ, moderate; þþþ, intense.
Two pathologists (EP and KB) independently evaluated immuno-
histochemical staining on randomly numbered slides.
The FITC-labelled anti-rabbit secondary antibodies (Jackson
ImmunoResearch Laboratories) were used for confocal micro-
scopy. Pictures were acquired with the Confocal Laser Scanning
Microscope (Olympus Optical Europe, Hamburg), equipped
with the Fluoview ver.2.1.39 software program (Olympus). The
Photoshop software (v6; Adobe System Inc.) was used to edit
viewing.
Statistical analysis
Intergroup differences in the mRNA values were analysed using
the Mann–Whitney’s U-test. The differences were considered
statistically significant at Po0.05.
RESULTS
RT–PCR and Western blot analysis
The expression of pendrin was determined in a series of normal
and pathological thyroid tissues. Pendrin mRNA was detected by
RT–real-time PCR in 49 out of 53 (92.4%) carcinomas, in the
range of 0.006–1.86 relative levels. In the normal paired tissues,
relative pendrin mRNA level ranged from 0.3 to 8.06 and
was significantly higher compared to cancer tissue (Po0.001)
(Figure 1). According to pendrin mRNA levels, the analysed
thyroid carcinomas could be divided into four subgroups. The first
two groups include cases with negative (4 out of 53; 7.5%) and low
pendrin mRNA expression, (12 out of 53; 22.6 %). The next group
comprises cases with mRNA levels close to the average value of
MNE for all 53 analysed tissues (27 out of 53, 51%; MNE range
from 0.1 to 0.6). In the fourth group of tissues, the relative pendrin
mRNA levels in cancer tissues were of the same extent as mRNA
levels detected in normal paired thyroid tissues (10 out of 53,
18.9%; MNE range from 0.9 to 2), Figure 1. In the group of
tumours with very low mRNA expression, the differences between
cancer and normal paired tissues were lower by a factor of 25–300.
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Figure 1 Relative level of pendrin mRNA expression in differentiated
thyroid carcinomas compared to the paired normal tissues.
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sIn the remaining cancer tissues, the PDS transcript levels were
lower by a factor of 1.5–10.
The expression of pendrin was confirmed at the protein level by
Western blot with site-specific pendrin antibodies. Pendrin protein
was detected in 35 out of 35 normal thyroid tissues, and in 26 out
of 35 tumours (Western blotting analysis was performed for only
35 tissues because the weight of 18 cancer tissues was very small
and therefore these tissues were not available for the Western blot
studies.). The intensity of the pendrin band was proportional to
the concentration of the membrane protein loaded (Figure 2A).
Affinity-purified polyclonal anti-pendrin antibodies under dena-
turating conditions revealed a single polypeptide band of 115kDa
in both normal and cancer tissues (Figure 2A and B). Western blot
signals obtained from six representative paired samples and 12
cancer samples of 35 are shown in Figure 2B. Using identical
amounts of protein allowed measurement of the relative quantity
of the pendrin with respect to intensity and size of pendrin bands.
The intensity of the immunostaining of pendrin bands was closely
related to the mRNA level assessed by quantitative real-time
RT–PCR. Values obtained by semiquantification of pendrin
protein expressed as arbitrary units and quantification of pendrin
transcript signals corresponding to the tumours and paired normal
tissues are shown in Figure 2C. Only cancer tissues with negative
and low mRNA levels were negative in Western blot with both
antibodies. In the remaining cancer samples, the pendrin band
intensity varied from very weak to strong (Figure 2B).
The average level of pendrin protein as estimated from Western
blot analysis was twice as low in cancer tissues as in paired normal
tissues and expressed in arbitrary units was 27.9736.3 vs
63.5748.4 (mean7s.e.m.) for the paired normal thyroid.
Immunochistochemistry for pendrin
The result of immunohistochemical analyses of the pendrin in
155 thyroid tissues are summarised in Table 1 and are shown in
Figure 3. In the normal thyroid, GD and NG tissues, the pendrin
staining was limited to the apical cell membrane (Figure 3A). One
of 15 follicular adenomas showed exclusively membranous
pendrin expression. In 10 of 15 (66.7%) adenomas, the expression
of pendrin protein was detected simultaneously in the cytoplasm
and at the apical cell membrane with extensive and moderate
immunostaining detected in half of all cases. Four of 15 adenomas
(26.7%) expressed pendrin protein in the cytoplasm only with
strong immunoreactivity detected in three cases. In a series of
differentiated thyroid carcinomas, 73.3% (11 out of 15) of FTC and
76.6% (23 out of 30) of PTC clearly showed pendrin protein
expression. Out of 11 follicular carcinomas, 10 (91%) expressed
pendrin protein exclusively in the cytoplasm, and one both in the
cytoplasm and at the apical cell membrane. In six of 10 FTC, the
immunostaining for pendrin was intensive and homogenously
distributed through the tumoral area, and in the remaining four
cases intermediate reactivity was observed. Three (20%) follicular
carcinomas were negative and one exhibited focal pendrin
immunostaining. Of 30 papillary carcinomas, 23 showed pendrin
protein expression. In all positive tumours, the pendrin protein
was localised exclusively in the cytoplasm. Out of these 23 cases,
19 PTC showed an intensive homogenous pendrin expression,
whereas in the remaining four cases moderate immunostaining
was found. Four (13.3%) papillary carcinomas were negative for
pendrin staining, and three showed focal reactivity (Table 1).
Pendrin protein immunodetection on paraffin-embedded sections
is shown in Figure 3. Affinity-purified anti-pendrin antibodies
specifically labelled pendrin located at the apical plasma mem-
branes of follicular cells of the normal thyroid (Figure 3A), NG
(Figure 3B) and GD (Figure 3C) tissues. In the normal thyroid, the
apical labelling was not uniform in both follicles and epithelial
cells. These stained cells likely correspond to functionally active
cells and follicles. In NGs (Figure 3B) and GD thyroids (Figure 3C),
immunostaining varied from one follicle to another and was
related to the size of the follicles (Figure 3B and C). The majority
of positive cells were in small follicles and in follicles with
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Figure 2 Pendrin expression in thyroid tissues. (A) Semiquantitative
immunodetection of pendrin protein in human thyroid tissues by Western
blotting. Increasing amounts of crude membrane preparation from the pool
of normal thyroid tissues was used for Western blot procedure. Arbitrary
units were assigned to each protein band following scanning. West Pico
signals were scanned and semiquantified as described in Material and
Methods. The relative amount of pendrin, expressed as arbitrary units, is
plotted as a function of the micrograms of the protein loaded. (B) Western
blotting analysis of pendrin protein expression in human thyroid tissues.
Protein (30mg) from particulate fractions prepared from normal thyroid
tissues (N), thyroid cancer tissues (C) and Graves’ disease tissues (GD)
were submitted to Western blot procedure using affinity-purified pendrin
antibodies (1mgml
 1) and West Pico substrate. Each lane was loaded with
an equal amount of the crude membrane protein (30mg) extracted from
cancer and paired normal tissues. Arrows show the pendrin bands (kDa).
(C) Comparative analysis of pendrin protein and PDS gene expression in a
series of 35 thyroid cancer (C) and normal paired (N) tissues. Relative
pendrin mRNA level expressed as MNE values (depicted in the right
panel); pendrin protein level in those tissues expressed as arbitrary units of
the luminance (left panel).
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sproliferative activity, whereas in large follicles the proportion
of positive cells was decreased (Figure 3B and C). In follicular
adenomas, pendrin-positive immunostaining was observed at
both, the apical plasma membranes and in the cytoplasm of 14
out of 15 cases (Figure 3E). In FTC and PTC, the pendrin protein
immunostaining of variable intensity was uniformly distributed
throughout the tumoral area and generally located in the
cytoplasm and probably membrane-associated. Figure 3F+I shows
cases of and PTCs with an extensive intracellular pendrin
expression, and Figure 3G+J illustrates follicular and papillary
Table 2 Pendrin expression and localisation in relation to tumour size and TNM (tumour-node-metastasis) in analysed thyroid neoplasm
Patient Sex/age Histology Tumour size (cm) TNM Pendrin immunostaining and localisation
BW F/66 PTC 1.3 T2aNo +++; c
SJ M/59 PTC 0.7 T1aNo ++; c
CH M F/72 PTC 5 5 4 T3a +++; c
UB F/39 PTC 2 1 1 T2a +++; c
LZ F/72 PTC 2.2 T2a +++; c
AA F/28 PTC 1.1 T2a ++; c
GW M/54 PTC 1.2 T2aNo +++; c
KA F/36 PTC 6; 2 T3b +++; c
KK F/23 PTC 1.5; 2 T2bNo +++; c
MM F/42 PTC 0.9 0.6 T1a +++; c
SM F/54 PTC 1.4 T2aNo 0
ZJ F/70 PTC 1.8 1.1 1 T2aNo ++; c
KZ F/63 PTC 1 1; 1 0.8 T1bNo +++; c
GJ F/53 PTC 4; 1 T2bNo ++; c
SG F/49 PTC 2.5 2 2 T2aNo 0
TP F/45 PTC 1.1; 1.5 T2bNo ++; c
GU F/31 PTC 1.6 T2aNo +++; c
SB F/49 PTC 1.6 1.2 T2aNo ++; c
DG F/38 PTC 1 T1aNo ++; c
KJ F/41 PTC 1.1 T2aNo +++; c
ZM F/21 PTC 2.5 T2aN1a 0
GJ F/51 PTC 2 T2aNo +++; c
WB F/22 PTC 5 6 6 T3aN1b 0
CA F/37 PTC 1.1 1.2 T2aNo +++; c
LA F/32 PTC 1.4 T2aNo +++; c
FJ F/47 PTC 1.8 T2aNo +++; c
BW F/31 PTC 2.2 T2aNo +++; c
KP F/27 PTC 1.3 T2aNo +++; c
WJ F/53 PTC 1.2 T2aNo +++; c
PM F/38 PTC 1.7 T2aNo +++; c
PT F/44 FTC 6 T3 ++; c
UB M/65 FTC 4.8 3.6 T3 0
BJ F/45 FTC 3 T2 +++; c
NE F/65 FTC 3.5 T2 +++; c
FE F/23 FTC 3 T2 ++; c
SL M/44 FTC 3.5 T2 +++; c
MB F/38 FTC 1.4 T2 +++; c
WM F/67 FTC 2.8 2.5 T2 0
SA F/30 FTC 1.6 T2 ++; c
WS F/58 FTC 2.8 T2 +++; c
GM F/53 FTC 1.3 T2 ++; c
DS F/47 FTC 1.4 1.8 T2 ++; c
PJ F/81 FTC 2.2 1.6 T2 +++; c+m
PA F/18 FTC 6 T2 +++; c
ZZ F/52 FTC 5.4 T3 0
DE F/33 F. adenoma 3 +++; c+m
TR F/57 F. adenoma 5 3 ++; c+m
SE F/54 F. adenoma 2.8 2.2 ++; c+m
SB F/48 F. adenoma 6 ++; c+m
DG F/44 F. adenoma 2.5 3.5 ++; c+m
LM F/49 F. adenoma 2 ++; c
UA F/64 F. adenoma 2 +++; c
SJ F/39 F. adenoma 1.2 ++; c
JM F/43 F. adenoma 2.8 1.9 +++; c
SB F/60 F. adenoma 2 +++; c+m
CA F/46 F. adenoma 2.3 ++; c
BJ F/37 F. adenoma 1.5 +++; c+m
JJ F/76 F. adenoma 3.2 +++; c
WM F/33 F. adenoma 5 +++; m
OB F/31 F. adenoma 3 +++; c
Intensity score: 0¼null; ++¼moderate; +++¼intense; c¼cytoplasmic; m¼membranous; F¼focal.
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reactivity was confirmed for all tissues analysed by confocal
fluorescent microscopy (Figure 3D – Graves’ tissue; H – FTC; KþL
– PTC carcinomas). There was no relationship between pendrin
expression or pendrin localisation and tumour stages (TNM), or
tumour size (Table 2). The analysed anaplastic carcinomas with
characteristics of the fully dedifferentiated tumours and no
expression of thyroid-specific genes as well as the few cases of
medullary carcinomas derived from C cells of neuronal crest origin
were negative for PDS gene transcript and pendrin protein in IHC
and Western blots.
DISCUSSION
The iodide transporting properties of pendrin in follicular cells
of the thyroid were suggested by experimental data on non-
polarised cell systems (Royaux et al, 2000; Yoshida et al, 2002), and
demonstrated very recently on a polarised cell system (Gillam et al,
2004). The latter study provided evidence for pendrin-mediated
apical iodide efflux from polarised mammalian cells loaded with
iodine (Gillam et al, 2004). Thus, the pendrin expression in
pathological thyroid tissues, particularly in cancerous tissues, is
of interest due to its iodide translocating activity, which serves as
one of the iodide suppliers for organification processes. Using
molecular and immunological methods, such as quantitative
RT–PCR, immunochistochemistry and Western blot, we have
clearly proved pendrin protein expression in a wide spectrum of
both normal and pathological tissues, mainly tumours.
Using the qualitative RT–PCR method, pendrin mRNA was
detected in 92% of thyroid carcinomas, including well-differen-
tiated papillary and follicular carcinomas. However, the PDS gene
expression indicated high variability. We found only slightly
altered or even equal mRNA expression in 19% of cancer samples
as compared with normal paired tissues. However, in the majority
(51%) of tumours, a reduction of mRNA levels by a factor of 1.5–
10 was observed, which is consistent with the results reported by
Porra et al, (2002). Pendred syndrome gene expression was
considerably lower in 23% of tumours. In some previous studies it
was found that the PDS transcript content in differentiated thyroid
tumours was decreased by a factor 2–1000, when compared to
normal thyroid tissues (Bidart et al, 2000; Mian et al, 2001). In
these studies, the immunochemical examination also revealed a
variability of the pendrin protein expression. However, in a large
Figure 3 Immunohistochemical analysis of expression and cellular distribution of pendrin in normal and pathological thyroid tissues. (A) Normal thyroid
tissue; the apical staining is heterogeneous inside and between follicles (original magnification  400; inset – peptide competition test control); (B)
immunostaining for pendrin in NG. The staining is restricted to the small proliferating follicles (original magnification  200; inset – peptide competition test
control); (C) Graves’ tissue with distinct apical staining pattern, especially observed in small follicles (original magnification  200; inset – peptide competition
test control); (D) immunostaining of pendrin in Graves’ tissue by confocal microscopy, FITC-labelled anti-rabbit secondary antibody were used. (E) Follicular
adenoma; immunostaining shift to the cytoplasm is observed (original magnification  400; inset – peptide competition test control); (F) Follicular
carcinoma; strong intracellular staining (original magnification  400); (G) Follicular carcinoma; moderate intracytoplasmic stain (original magnification
 400); (H) immunofluorescence of FTC with strong intracytoplasmic pendrin expression (original magnification  40); (I) Papillary carcinoma; strong
intracellular staining (original magnification  400; inset – peptide precipitation test control); (J) Papillary thyroid carcinoma; moderate cytoplasmic staining
(original magnification  200); (K) immunofluorescence of PTC with strong pendrin expression (original magnification  40); (L) immunofluorescence of
PTC with moderate pendrin expression (original magnification  40).
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sproportion of the tumours, a heterogeneous weak staining was
observed. Also, Western blot assay showed individual variability
between samples, and the protein expression level was closely
associated with the relative mRNA expression as estimated by
quantitative real-time PCR. Pendrin protein immunorecativity was
found in all thyroid cancer tissues with MNE above 0.2. Using a
similar method, Porra et al (2002) observed that protein levels
corroborated RT–PCR data in the majority of PTSc. Pendrin was
clearly demonstrated by means of immunohistochemic method
in 73.3% of FTCs and 76.7% of PTCs with overall intracellular
localisation. The results of the Western blot and IHC as
comparative methods were complementary.
Our findings, which confirm to previous findings on the high
variability of the PDS transcript level in differentiated thyroid
carcinomas, were different from those of some previous studies
(Bidart et al, 2000; Mian et al, 2001; Kondo et al, 2003). The
differences can be explained by the use of different antibodies.
In our study, we used high-affinity antigen-purified antibodies
against amino- and carboxyl-termini of the pendrin molecule
both located intracellularly (Gillam et al, 2004). Both antibodies
displayed an identical pattern of reactivity in IHC and Western
blot. The same patterns of pendrin distribution in thyroid
carcinoma cells was observed using seven different anti-pendrin
antibodies produced by us (data not shown). The immunohisto-
chemical study reflects previous findings which show that pendrin
is located at the apical pole of the follicular cells (Bidart et al,
2000; Royaux et al, 2000; Porra et al, 2002). This localisation is in
agreement with the localisation of key proteins involved in the
processes of thyroid hormone biosynthesis to which pendrin is
thought to contribute (Royaux et al, 2000; Taurog, 2000; Yoshida
et al, 2002). In the normal thyroid, only parts of the columnar
follicular cells, which are considered to be functionally active, were
stained. In NG and GD thyroids, the majority of follicular cells
were intensely stained, especially in the small and proliferative
follicles. This suggests that pendrin expression may be related to
the functional status of the follicle and that of the single follicular
cell. The major observation in our immunohistochemical analysis,
however, is that in almost all (470%) differentiated thyroid
tumours, both follicular and papillary thyroid carcinomas, which
preserved pendrin expression, the protein was present exclusively
in the intracellular compartment. It should be noted that apical
staining for pendrin was detected in normal thyroid tissues
adjacent to the tumour analysed. The peptide immunoprecipita-
tion tests resulted also in negative immunolabelling, which
excludes technical pitfalls during immunostaining procedures.
Gerard et al (2003) also reported an impairment of pendrin protein
expression in pathological thyroids. They detected pendrin only in
follicular carcinomas, at a level lower than that of normal thyroids.
In our series of carcinomas of both histotypes, PTCs and FTCs,
the incidence of pendrin-positive IHC was almost identical. We
also analysed the relationship between pendrin protein expression
levels and tumour size and tumour stage. However, no association
was detected.
In follicular adenomas, a shift of pendrin localisation from the
apical membrane to the cytoplasm was observed suggesting partial
retention of protein in intracellular compartments, most likely
membrane-associated. Although individual heterogeneity in the
expression of pendrin was observed, all tissues expressing
simultaneously a cytoplasmic and membranous localisation of
pendrin had characteristics of cold adenomas.
Active translocation of iodide requires properly targeted
pendrin at the apical plasma membrane (Taylor et al, 2002; Gillam
et al, 2004). Therefore, the observation that in the majority of
the analysed differentiated thyroid carcinomas pendrin remains
in an intracellular membrane compartment may suggest that in
these tissues pendrin is nonfunctional. Since improper targeting
of pendrin was observed in almost all differentiated thyroid
carcinomas and since pendrin mRNA and protein expression were
comparable to noncancerous thyroid tissues, one may speculate
that this is a general phenomenon of trafficking of pendrin in
thyroid neoplasm. The causes responsible for alterations of the
intracellular distribution of pendrin remain unknown. Several
mechanisms could account for intracellular retention of pendrin in
thyroid tumours cells. For example, changes in proper folding and
assembly of protein might be considered. However, the methods
we applied cannot give any information on how far the
cytoplasmic pendrin is altered by sequence, conformation and
function or if cofactors for trafficking the molecule are affected.
Further studies are necessary to elucidate the detailed mechanism/
s by which this protein expression is regulated in thyroid
differentiated carcinoma cells and may contribute to the carcino-
genesis and the development of these tumours. Investigations in
this respect go beyond the possibilities presented by tissues
specimens obtained from surgery.
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